Therapeutic Asset Ratings

361 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
TRIPRO-AMYLIN Obesity	University Hospital, Gentofte, Copenhagen	P2/3	BB (65)
Empagliflozin Obesity	Ali Aminian	P4	BB (64)
Hydrochlorothiazide Obesity	University of Kansas Medical Center	P4	BB (64)
Levonorgestrel Obesity	Amgen	P4	BB (64)
LIDOCAINE Obesity	IVO JURISIC	P4	BB (64)
Lipitor Obesity	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P4	BB (64)
Sitagliptin Obesity	Brigham and Women's Hospital	P4	BB (64)
VITAMIN D Obesity	Agricultural University of Athens	P4	BB (64)
Retatrutide Obesity	Hudson Biotech	P3	BB (64)
Desflurane Obesity	Medical University of Gdansk	P4	B (63)
Genotropin Obesity	Columbia University	P4	B (63)
NEPENTHE Obesity	Kirsehir Ahi Evran Universitesi	P4	B (63)
Pioglitazone Obesity	Mayo Clinic	P4	B (63)
gzr18 Obesity	Gan & Lee Pharmaceuticals.	P3	B (63)
Hrs-7535 Obesity	Shandong Suncadia Medicine Co., Ltd.	P3	B (63)
Mdr-001 Obesity	MindRank AI Ltd	P3	B (63)
Setmelanotide Obesity	Massachusetts General Hospital	P3	B (63)
Enoxaparin Obesity	University College Dublin	P4	B (62)
Tadalafil Obesity	Philip Kern	P4	B (62)
VALSARTAN Obesity	ARKAY Therapeutics	P4	B (62)
Calcium folinate pentahydrate Obesity	University College Dublin	P4	B (61)
CIS-DIAMMINEDICHLOROPLATINUM II Obesity	University College Dublin	P4	B (61)
FENTANYL Obesity	IVO JURISIC	P4	B (61)
FLUOROURACILUM Obesity	University College Dublin	P4	B (61)
GLUCOSE, ANHYDROUS Obesity	Columbia University	P4	B (61)

Showing 26 to 50 of 361 assets